Function through Synthesis-Informed Design

Abstract

ConspectusIn 1996, a snapshot of the field of synthesis was provided by many of its thought leaders in a Chemical Reviews thematic issue on “Frontiers in Organic Synthesis”. This Accounts of Chemical Research thematic issue on “Synthesis, Design, and Molecular Function” is intended to provide further perspective now from well into the 21st century. Much has happened in the past few decades. The targets, methods, strategies, reagents, procedures, goals, funding, practices, and practitioners of synthesis have changed, some in dramatic ways as documented in impressive contributions to this issue. However, a constant for most synthesis studies continues to be the goal of achieving function with synthetic economy. Whether in the form of new catalysts, reagents, therapeutic leads, diagnostics, drug delivery systems, imaging agents, sensors, materials, energy generation and storage systems, bioremediation strategies, or molecules that challenge old theories or test new ones, the function of a target has been and continues to be a major and compelling justification for its synthesis. While the targets of synthesis have historically been heavily represented by natural products, increasingly design, often inspired by natural structures, is providing a new source of target structures exhibiting new or natural functions and new or natural synthetic challenges. Complementing isolation and screening approaches to new target identification, design enables one to create targets de novo with an emphasis on sought-after function and synthetic innovation with step-economy. Design provides choice. It allows one to determine how close a synthesis will come to the ideal synthesis and how close a structure will come to the ideal function.In this Account, we address studies in our laboratory on function-oriented synthesis (FOS), a strategy to achieve function by design and with synthetic economy. By starting with function rather than structure, FOS places an initial emphasis on target design, thereby harnessing the power of chemists and computers to create new structures with desired functions that could be prepared in a simple, safe, economical, and green, if not ideal, fashion. Reported herein are examples of FOS associated with (a) molecular recognition, leading to the first designed phorbol-inspired protein kinase C regulatory ligands, the first designed bryostatin analogs, the newest bryologs, and a new family of designed kinase inhibitors, (b) target modification, leading to highly simplified but functionally competent photonucleases—molecules that cleave DNA upon photoactivation, (c) drug delivery, leading to cell penetrating molecular transporters, molecules that ferry other attached or complexed molecules across biological barriers, and (d) new reactivity-regenerating reagents in the form of functional equivalents of butatrienes, reagents that allow for back-to-back three-component cycloaddition reactions, thus achieving structural complexity and value with step-economy. While retrosynthetic analysis seeks to identify the best ...

Natural Products as Platforms To Overcome Antibiotic Resistance

“…55 Several highly successful drugs have been developed using this strategy, including Lipitor, which was designed from a naturally occurring statin. 56 …”

Capturing Biological Activity in Natural Product Fragments by Chemical Synthesis

“…To date, over 100 analogues have been synthesized and screened for various activities, and nearly one‐third exhibit single‐digit nanomolar or even picomolar potencies for PKC binding 6d. These studies were primarily driven by the guiding principle that the bryostatin core structure could be divided into the upper “binding” or “recognition domain” (C1–C14) and lower “spacer domain” (C15–C27) according to its interactions with PKC (Figure 9).…”

Inhibition of Chikungunya Virus-Induced Cell Death by Salicylate-Derived Bryostatin Analogues Provides Additional Evidence for a PKC-Independent Pathway

“…15 Syntheses of natural bryostatins are improving but have yet to positively impact the clinical supply or further clinical advancement. Using a function-oriented design and synthesis approach, 7 the Wender group has designed bryostatin analogues (bryologs) that are synthetically more accessible, superior to bryostatin in cell culture, animals, and primary human cells, and better tolerated. 8,16 This preliminary evaluation of the anti-CHIKV activity of the newest bryologs 9 indicates that they represent promising leads, on par with the best leads reported to date (EC 50 of ca.…”